US Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702; email:
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:329-348. doi: 10.1146/annurev-pharmtox-010716-105055. Epub 2016 Dec 7.
Despite the unprecedented Ebola virus outbreak response in West Africa, no Ebola medical countermeasures have been approved by the US Food and Drug Administration. However, multiple valuable lessons have been learned about the conduct of clinical research in a resource-poor, high risk-pathogen setting. Numerous therapeutics were explored or developed during the outbreak, including repurposed drugs, nucleoside and nucleotide analogues (BCX4430, brincidofovir, favipiravir, and GS-5734), nucleic acid-based drugs (TKM-Ebola and AVI-7537), and immunotherapeutics (convalescent plasma and ZMapp). We review Ebola therapeutics progress in the aftermath of the West Africa Ebola virus outbreak and attempt to offer a glimpse of a path forward.
尽管在西非开展了史无前例的埃博拉病毒疫情应对行动，但美国食品和药物管理局尚未批准任何埃博拉医疗对策。然而，在资源匮乏、高危病原体环境中开展临床研究方面，我们汲取了许多宝贵经验。疫情期间，曾探索或研发了多种治疗方法，包括已上市药物再利用、核苷（酸）类似物（BCX4430、溴夫定、法匹拉韦和 GS-5734）、核酸类药物（TKM-Ebola 和 AVI-7537）和免疫疗法（恢复期血浆和ZMapp）。我们回顾了西非埃博拉病毒疫情过后埃博拉治疗方法的进展，并尝试展望未来的发展方向。
